Compare Enveric Biosciences Inc (ENVB) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares Semiconductor ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares Semiconductor ETF trades at $573.85 (market cap $48.60B). The key difference: iShares Semiconductor ETF is far larger — about 7264.6× Enveric Biosciences Inc's market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares Semiconductor ETF for 46 Days on average.
| ENVB | SOXX | |
|---|---|---|
Market Cap | $6.69M | $48.60B |
Volume | 41,141 | 4,851,301 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $655.01 |
52-Week Low | $1.27 | $268.10 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SOXX trades at $582.94, down 1.1% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI levels. The semiconductor ETF benefits from strong AI-driven demand, with recent news highlighting sector momentum and major acquisitions. A 1:3 stock split is scheduled for November 2026, while dividend payments remain modest.
The outlook remains positive due to robust AI infrastructure growth projections, though high valuations and concentration risks warrant caution. Key risks include Michael Burry's bearish bets and potential sector rotation. Analyst sentiment is generally favorable, with earnings growth expected to support further upside if macroeconomic conditions remain stable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
